AAIC 2025 Abstract
TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer’s disease
Trial in peopleInterventions
Abstract
Background: Developing potent therapies that reduce amyloid plaques has been shown as one means of producing clinical benefit in the early stages of symptomatic Alzheimer’s disease (AD).
